Goserelin acetate
Highest phase reached
Approved
Drug type
Protein
First approval year
1989
- First approval year
- 1989
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Protein
- Drug name
- Goserelin acetate
- Molecular weight
- 1,329.48
- Structure (SMILES)
- CC(=O)O.CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)NNC(N)=O
- novgos
- Novgos
- zoladex
- Zoladex
- zoladex la
- Zoladex la
- 1 9 luteinizing hormone releasing factor swine 6 o 1 1 dimethylethyl d serine 2 aminocarbonyl hydrazide acetate salt
- 1-9-LUTEINIZING HORMONE-RELEASING FACTOR (SWINE), 6-(O-(1,1-DIMETHYLETHYL)-D-SERINE)-, 2-(AMINOCARBONYL)HYDRAZIDE, ACETATE (SALT)
- casodex and zoladex or lupron
- fertilan
- Fertilan
- GnRH analogue (Zoladex)
- goserelin acetate
- Goserelin acetate
- GOSERELIN ACETATE [JAN]
- GOSERELIN ACETATE [MART.]
- GOSERELIN ACETATE [ORANGE BOOK]
- GOSERELIN ACETATE [USP MONOGRAPH]
- GOSERELIN ACETATE [USP-RS]
- GOSERELIN ACETATE [VANDF]
- Goserelin acetate [WHO-DD]
- goserelin acetate jan
- goserelin acetate mart
- goserelin acetate orange book
- goserelin acetate usp monograph
- goserelin acetate usp rs
- goserelin acetate vandf
- goserelin acetate who dd
- ZD9393 (Zoladex) 10.8 mg
- ZD9393 (Zoladex) 3.6 mg
- Zoladex
And 8 more, listed on the interactive page.
- CAS registry numbers
- 145781-92-6
- ChEMBL ID
- CHEMBL1200501
- InChIKey
- IKDXDQDKCZPQSZ-JHYYTBFNSA-N
- PubChem compound IDs
- 16052011
- RxNorm IDs (RxCUI)
- 203146
- FDA ingredient codes (UNII)
- 6YUU2PV0U8
- Applicant
- TERSERA
- Approval date
- 29 Dec 1989
- Application number
- NDA019726
- First in class
- No
- Orphan designation
- No
- Availability
- Prescription only
- Drug name stem
- -relin
Administration routes
- Parenteral
Mechanisms of action
- Mechanism
- Gonadotropin-releasing hormone receptor agonist
- Action type
- Agonist
- Target
- Gonadotropin-releasing hormone receptor
- Protein identifier
- P30968
Open Targets mechanisms
- Mechanism
- Gonadotropin-releasing hormone receptor agonist
- Action type
- Agonist
- Target
- Gonadotropin-releasing hormone receptor
- Condition
- Metabolic Syndrome
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000195
- Subject identifier
- D024821
- Condition
- Prostatic Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000196
- Subject identifier
- D011471
- Condition
- Breast Neoplasms
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000305
- Subject identifier
- D001943
- Condition
- Carcinoma
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000313
- Subject identifier
- D002277
- Condition
- Infertility
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000545
- Subject identifier
- D007246
- Condition
- Prostatic Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000673
- Subject identifier
- D011471
- Condition
- Prostatic Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0001663
- Subject identifier
- D011471
- Condition
- Breast Neoplasms, Male
- Highest recorded phase
- 1
- Condition identifier
- EFO:0006861
- Subject identifier
- D018567
- Condition
- Menopause
- Highest recorded phase
- 3
- Condition identifier
- GO:0042697
- Subject identifier
- D008593
- Condition
- Salivary Gland Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0000521
- Subject identifier
- D012468
- Condition
- Peritoneal Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0002087
- Subject identifier
- D010534
- Condition
- Fallopian Tube Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0002158
- Subject identifier
- D005185
- Condition
- Breast Neoplasms
- Highest recorded phase
- 4
- Condition identifier
- MONDO:0007254
- Subject identifier
- D001943
- Condition
- Ovarian Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0008170
- Subject identifier
- D010051
- Condition
- Prostatic Neoplasms, Castration-Resistant
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0008315
- Subject identifier
- D064129
- Condition identifier
- EFO_0000195
- Condition identifier
- EFO_0000305
- Condition identifier
- EFO_0000313
- Condition identifier
- EFO_0000545
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000673
- Highest recorded phase
- 2
- Condition identifier
- EFO_0001663
- Highest recorded phase
- 3
- Condition identifier
- GO_0042697
- Highest recorded phase
- 3
- Condition identifier
- HP_0000789
- Condition identifier
- HP_0000855
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0000521
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0004989
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0004993
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0005082
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005148
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005159
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005494
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0006512
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0007254
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0008315
- Highest recorded phase
- 3
- Event
- abdominal lymphadenopathy
- Reports
- 27
- Reporting signal score
- 103.407
- Event
- bone lesion
- Reports
- 31
- Reporting signal score
- 78.6531
- Event
- breast cancer
- Reports
- 101
- Reporting signal score
- 161.778
- Event
- breast cancer metastatic
- Reports
- 79
- Reporting signal score
- 236.138
- Event
- carcinoid tumour pulmonary
- Reports
- 13
- Reporting signal score
- 55.2038
- Event
- circumstance or information capable of leading to device use error
- Reports
- 14
- Reporting signal score
- 54.8901
- Event
- cyp3a4 polymorphism
- Reports
- 8
- Reporting signal score
- 50.0075
- Event
- disease progression
- Reports
- 109
- Reporting signal score
- 83.6539
- Event
- expulsion of medication
- Reports
- 24
- Reporting signal score
- 121.521
- Event
- hot flush
- Reports
- 201
- Reporting signal score
- 413.375
- Event
- interstitial lung disease
- Reports
- 80
- Reporting signal score
- 78.1312
- Event
- lymphadenopathy
- Reports
- 49
- Reporting signal score
- 46.0998
- Event
- malignant neoplasm progression
- Reports
- 435
- Reporting signal score
- 1,046.25
- Event
- metastases to bone
- Reports
- 183
- Reporting signal score
- 559.424
- Event
- metastases to central nervous system
- Reports
- 34
- Reporting signal score
- 56.4817
- Event
- metastases to liver
- Reports
- 133
- Reporting signal score
- 366.479
- Event
- metastases to lung
- Reports
- 46
- Reporting signal score
- 97.0313
- Event
- metastases to lymph nodes
- Reports
- 49
- Reporting signal score
- 125.561
- Event
- metastases to peritoneum
- Reports
- 25
- Reporting signal score
- 72.8818
- Event
- metastases to skin
- Reports
- 25
- Reporting signal score
- 87.4686
- Event
- metastases to spine
- Reports
- 29
- Reporting signal score
- 86.4965
- Event
- neoplasm progression
- Reports
- 53
- Reporting signal score
- 65.6304
- Event
- neutropenia
- Reports
- 146
- Reporting signal score
- 84.963
- Event
- ovarian hyperstimulation syndrome
- Reports
- 44
- Reporting signal score
- 126.997
- Event
- pik3ca-activated mutation
- Reports
- 29
- Reporting signal score
- 137.485
And 4 more, listed on the interactive page.
- NCT00002460
- NCT00002580
- NCT00002582
- NCT00010010
- NCT00047099
- NCT00053911
- NCT00217659
- NCT00303524
- NCT00322348
- NCT00398489
- NCT00605267
- NCT00888082
- NCT01073865
- NCT01368263
- NCT01674140
- NCT01712893
- NCT02626507
- NCT03664895
- NCT03936933
- NCT05438810
- NCT05439499
- NCT00002597
- NCT00002651
- NCT00002881
- NCT00003394
And 66 more, listed on the interactive page.
- Dose
- 3.6 mg
- Route
- Subcutaneous
- How often
- Every 28 days
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Heavy atoms
- 95
- Molecular formula
- C61H88N18O16
- Monoisotopic mass
- 1328.66256879
- Natural product
- No
- 70720-950
- 70720-951
- Recorded assays
- 190
- Active assays
- 0
- Antineoplastic Agents, Hormonal
Related records
Trials (258)
- (Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
- A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy
- A Degarelix Trial in Patients With Prostate Cancer
- A Phase Ib Dose Escalation Study of the Combination of LEE011 With Letrozole and Dose Expansion of LEE011 With Hormonal Therapy for the Treatment of Pre-(With Goserelin) and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer
- A Phase II Study of Androgen Deprivation Therapy With or Without Palbociclib in RB-Positive Metastatic Prostate Cancer
- A Phase II Study of PROSTVAC-V (Vaccinia)/TRICOM and PROSTVAC-F (Fowlpox)/TRICOM With GM-CSF in Patients With PSA Progression After Local Therapy for Prostate Cancer
- A Pilot Study of Hormonal Therapy Combined With Central Memory T Cells (Tcm) for Patients With Advanced Prostate Cancer
- A Prospective Observational Study About Adjuvant or Neoadjuvant Chemotherapy Related Adverse Effects in Premenopausal Breast Cancer Patients
- A Prospective, Single-Arm Study to Evaluate the Efficacy and Safety of Zoladex 3.6mg Combined With CEF Chemotherapy as Neo-Adjuvant Therapy in Hormone Responsive, Premenopausal, Operable Breast Cancer
- A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
- A Study of Neoadjuvant Hormone Therapy in Patient With Advanced Prostate Cancer Undergoing Radical Prostatectomy.
- A Study to Assess LY01005 Versus Goserelin Comparator (ZOLADEX®) in Patients With Prostate Cancer
- A Study to Assess the Bioequivalence of Follitropin Alfa Solution in Pen and Follitropin Alfa Powder in Vial in Healthy Downregulated Male Participants
- A Study to Compare the Effect of ASP3550 With Goserelin in Patients With Prostate Cancer
- A Trial of Degarelix in Patients With Prostate Cancer
- A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer
- Abarelix Versus Goserelin Plus Bicalutamide in Patients With Advanced or Metastatic Prostate Cancer
- Abiraterone Prednisone and Hormonal Therapy Before and During Radiation Therapy in Localized Prostate Cancer
- Adaptions and Resiliency to Multi-Stressor OpeRations
- Adjuvant AI Combined With Zoladex
Approved for (3)
- Breast cancer
- Breast carcinoma
- Carcinoma
In development for (11)
- Fallopian tube cancer Phase 2
- Infertility disorder Phase 3
- Male breast carcinoma Phase 1
- Metabolic syndrome X Phase 1
- Metastatic prostate carcinoma Phase 3
- Ovarian cancer Phase 2
- Peritoneum cancer Phase 2
- Prostate adenocarcinoma Phase 3
- Prostate cancer Phase 3
- Prostate carcinoma Phase 3
- Salivary gland carcinoma Phase 2
Targets (1)
- GNRHR Gonadotropin-releasing hormone receptor agonist